In another study by Gangadhara et al. [60], the drug response to endocrine agents (tamoxifen, fulvestrant) and trastuzumab was assessed for ER-positive/HER2-positive breast cancer 2D and 3D models. The gene discussed is ERBB2; the disease is breast cancer.